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Abstract
Background: The aim of this randomized controlled trial was to compare the efficacy of extended letrozole
regimen with clomiphene citrate in women with unexplained infertility undergoing superovulation and intrauterine
insemination (IUI).
Methods: Two hundred and fourteen patients with unexplained infertility were randomized into two equal groups
using computer generated list and were treated by either letrozole 2.5 mg/day from cycle day 1 to 9 (extended
letrozole group, 211 cycles) or clomiphene citrate 100 mg/day from cycle day 3 to 7 (clomiphene citrate group,210
cycles). Intrauterine insemination was performed 36 to 40 hours after HCG administration.
Results: Both groups were comparable with regard to number of mature follicles (2.24 +/- 0.80 Vs 2.13 +/- 0.76)
and the day of HCG administration. Serum estradiol was significantly greater in clomiphene citrate group (356 +/-
151 Vs 822 +/- 302 pg/ml, P = < 0.001) and the endometrial thickness was significantly greater in extended
letrozole group (9.10 +/- 1.84 Vs 8.18 +/- 1.93 mm, P = < 0.001).The pregnancy rate per cycle and cumulative
pregnancy rate were significantly greater in extended letrozole group (18.96% Vs 11.43% and 37.73% Vs 22.86%,
respectively).
Conclusion: The extended letrozole regimen had a superior efficacy as compared with clomiphene citrate in
patients of unexplained infertility undergoing superovulation and IUI.
Trial registration: ClinicalTrials.gov, NCT01232075
Background
Unexplained infertility is one of the most frequent infer-
tility diagnoses encountered by the gynaecologists. Var-
ious studies reported that 10 to 30% of infertile couples
have unexplained infertility [1,2].
Superovulation and intrauterine insemination (IUI) is
an effective treatment for women with unexplained
infertility [3]. Superovulation increases the probability of
pregnancy by increasing the number of oocytes suitable
for fertilization or by correcting any subtle defect in
ovulation. Furthermore, IUI increases the concentration
of active motile sperms reaching the fallopian tubes and
overcomes male factors or cervical factors of infertility
not detected by conventional infertility tests [4].
For more than four decades, clomiphene citrate has
been the first line therapy for induction of ovulation in
women with anovulatory infertility and for superovula-
tion in couples with unexplained infertility, mild endo-
metriosis and mild male factor of infertility. Clomiphene
citrate is cheap, orally administered and is associated
with very low risk of high-order multiple gestation and
severe ovarian hyperstimulation syndrome (OHSS)[5,6].
However, clomiphene citrate induces prolonged estrogen
receptors depletion and therefore exerts antiestrogenic
effect on estrogen target tissues as endocervix and endo-
metrium. Several studies revealed that clomiphene
citrate has a deleterious effect on cervical mucus
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resulting in decreased uterine blood flow, endometrial
thinning, luteal phase defect and implantation failure
[7,8].
During the past decade, letrozole (aromatase inhibitor
approved by FDA for the treatment of postmenopausal
women with breast cancer) has been successfully used
for induction of ovulation in anovulatory patients with
polycystic ovary syndrome (PCOS) and for augmenta-
t i o no fo v u l a t i o ni no v u l a t o r yw o m e n[ 6 , 9 ] .I nc o n t r a s t
to clomiphene citrate, letrozole is rapidly eliminated
from the body and does not deplete estrogen receptors
and therefore has no adverse effect on endometrium or
endocervix [10,11].
Several studies revealed that letrozole can be used as
an alternative to clomiphene citrate for superovulation
in patients with unexplained infertility [12,13]. A meta-
analysis of seven randomized controlled trials comparing
aromatase inhibitors (letrozole or anastrozole) with clo-
miphene citrate for superovulation in patients with
unexplained infertility undergoing IUI revealed that the
pregnancy rate was comparable between both manage-
ment options [14].
The optimal dose and duration of letrozole adminis-
tration for superovulation in patients with unexplained
infertility are still not clear. In various studies reporting
the use of letrozole for superovulation, letrozole was
administered from cycle 3 to 7 with daily dose ranging
from 2.5 mg to 7.5 mg [6]. In a randomized controlled
trial, Al-Fadhli et al found that the pregnancy rate was
significantly higher in patients with unexplained inferti-
lity treated with 5 mg/day compared with those treated
with 2.5 mg/day [15]. On the other hand, a recent ran-
domized controlled trial revealed that the pregnancy
rates were comparable in three groups of patients with
unexplained infertility treated with three different doses
of letrozole (2.5, 5 or 7.5 mg/day) [16].
In a recent study, Badawy et al reported that the
extended letrozole regimen (2.5 mg/day from cycle day
1 to10) resulted in higher pregnancy rate compared with
short high dose letrozole regimen (5 mg/day for 5 days)
in clomiphene-resistant women with polycystic ovary
syndrome [17].
The aim of this randomized controlled trial was to
compare the efficacy of extended letrozole regimen (2.5
mg/day from cycle day 1 to 9) with clomiphene citrate
(100 mg/day from cycle day 3 to 7) in women with
unexplained infertility undergoing superovulation and
IUI.
Methods
This prospective, assessor blinded, allocation concealed,
multicenter, two arm randomized controlled trial
included 214 women (421 cycles) with unexplained
infertility among those attending the outpatient clinic of
Cairo university hospital and Ahmed Elgazzar hospital,
Cairo, Egypt between September 2008 and December
2010. The study protocol was approved by ethics com-
mittees of both hospitals. The patients were counselled
about the benefits and risks of letrozole and clomiphene
citrate therapy and informed consent was obtained
before randomization.
Patients with unexplained infertility and at least one
year of infertility were included in the study. All the
patients had patent fallopian tubes detected by hystero-
salpingography and/or laparoscopy, normal ovulation
confirmed by midluteal progesterone level more than 5
ng/ml and normal hormonal profile (FSH, LH, prolactin
and TSH) in the early follicular phase. All the male part-
ners had normal semen analysis according to WHO cri-
teria [18].
Our exclusion criteria were patients with irregular
cycles, ovarian cysts, PCOS, endometriosis, FSH >10
mIU/ml, age less than 18 years or more than 37 years,
previous IUI cycles and liver or kidney diseases.
Patients were randomly allocated to extended letrozole
group or clomiphene citrate group using a computer
generated randomization list and sequentially numbered
opaque sealed envelopes, each containing the allocation
information written on a card. Envelopes were opened
sequentially by a study nurse to allocate patients to the
assigned group. The extended letrozole group included
107 patients (211 cycles) who were treated with letro-
zole (Femara; Novartis pharma AG, Basle, Switzerland)
2 . 5m g / d a yf r o mc y c l ed a y1t o9 .T h ec l o m i p h e n e
citrate group included 107 patients (210 cycles) who
were treated with clomiphene citrate (Clomid; Aventis
pharma S.AE, Global Napi pharmaceuticals, Cairo,
Egypt) 100 mg/day from cycle day 3 to 7. All the
patients underwent 1 to 3 IUI cycles.
Human chorionic gonadotropin (Pregnyl; N.V. Orga-
non, Oss, Holland) (10.000 IU/I.M) was administered to
trigger ovulation when at least one follicle measured
more than 18 mm in mean diameter. Intrauterine inse-
mination was performed 36 - 40 hours after HCG injec-
tion using soft tip catheter. Serum B-subunit HCG was
measured 2 weeks after IUI to diagnose pregnancy.
Ultrasound examination was performed 5 weeks after
IUI to confirm the presence of fetal cardiac activity and
to exclude ectopic pregnancy.
Starting from cycle day 9, ultrasound scans were
repeated daily to monitor follicle growth. Serum estra-
diol and endometrial thickness were measured on the
day of HCG administration. Endometrial thickness was
measured at the greatest diameter perpendicular to the
midsagittal plane in the fundal region.
The doctor responsible for ultrasound examination (U.
M. Fouda) was blinded to the treatment protocol. The
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not blinded to the treatment protocol.
The primary end point was the clinical pregnancy rate
(presence of gestational sac in uterine cavity detected by
transvaginal ultrasound). The secondary end points were
the number of follicles with mean diameter more than
18 mm, serum estradiol and endometrial thickness on
the day of HCG administration, ongoing pregnancy rate
(pregnancies continued beyond 20 weeks gestation),
miscarriage rate(termination of pregnancy before the
20
th gestational weeks), ectopic pregnancy rate and mul-
tiple pregnancy rate.
Sample size calculation
The most recent and largest randomized controlled trial
at the time of study design was used for sample size cal-
culation. Badawy et al reported that the cumulative clin-
ical pregnancy rate in 207 patients (404 cycles, 1.95
cycle/woman) with unexplained infertility undergoing
superovulation and IUI was 35.6% when clomiphene
citrate was used for superovulation [19]. We considered
that 20% increase in cumulative clinical pregnancy in
favour of extended letrozoler e g i m e nw o u l db eo fc l i n i -
cal significance. To detect 20% difference in cumulative
pregnancy rate between extended letrozole group and
clomiphene citrate group (55.6% Vs 35.6%), each group
should include 97 patients to give the study 80% power
at the 5% significance level. We expected that the drop-
out incidence would be 10%, therefore 107 patients were
included in each group.
Statistical analysis
SPSS (Statistical Package for the Social Science; SPSS
Inc., Chicago, IL, USA) statistical program for Microsoft
Windows was used for statistical calculations. Compari-
son of quantitative variables between the study groups
was done using Student’s t-test for independent samples
when normally distributed. For comparing categorical
data, the Chi-square (c
2) test was performed. Yates cor-
rection equation was used instead, when the expected
frequency was less than 5. A probability value (p value)
less than 0.05 was considered statistically significant.
Results
A total of 214 patients (421 cycles) were recruited to the
study with 107 patients randomized to each group. Two
patients in clomiphene citrate group and one patient in
extended letrozole group withdrew from the study. The
mean number of cycles per woman was 1.99 in extended
letrozole group and 2 in clomiphene citrate group. The
flow of patients through the study is shown in Figure 1.
Table 1 shows the demographic criteria of both
groups. There were no significant differences between
both groups with respect to age, body mass index
(BMI), duration of infertility, percentage of patients with
primary or secondary infertility and baseline hormonal
profile.
Both groups were comparable with regard to number
of follicles > 18 mm on the day of HCG administration
(2.24 ± 0.80 Vs. 2.13 ± 0.76, P = 0.154). Serum estradiol
was significantly lower in extended letrozole group (356
±1 5 1V s .8 2 2±3 0 2p g / m l ,P = < 0.001) and the endo-
metrial thickness was significantly greater in extended
letrozole group (9.10 ± 1.84 Vs. 8.18 ± 1.93 mm, P =<
0.001) (Table 2).
The pregnancy rate per cycle and the cumulative preg-
nancy rate were significantly higher in extended letro-
zole group compared with clomiphene citrate group
(18.96% Vs 11.43% and 37.73% Vs 22.86%, respectively).
Five spontaneous abortions occurred in extended letro-
zole group and 4 spontaneous abortions occurred in clo-
miphene citrate group. There were 4 twin pregnancies
in extended letrozole group and 3 twin pregnancies in
clomiphene citrate group. No cases with ectopic preg-
nancies or ovarian hyperstimulation syndrome were
reported in both groups. All the neonates were exam-
ined by a paediatrician after delivery. No congenital
anomalies were detected (Table 3).
Discussion
To the best of our knowledge, this is the first study
comparing extended letrozole regimen with clomiphene
citrate for superovulation in patients with unexplained
infertility undergoing IUI. The results of our study
revealed that the extended letrozole regimen has a
superior efficacy as compared with clomiphene citrate.
Letrozole is a third generation, potent, reversible, non-
steroidal aromatase inhibitor. Letrozole administration
in early follicular phase blocks estrogen syntheses by
inhibiting aromatase enzyme which catalyses the conver-
sion of androstenedione and testosterone to estrone and
estradiol. The drop in the circulating estrogens levels
(produced by the ovary and by conversion of androgens
in adipose tissues) and locally produced estrogens in
brain releases the hypothalamo-pituitary axis from estro-
genic negative feedback on FSH and LH release. The
increase in FSH secretion stimulates the recruitment
and growth of antral follicles [20]. Furthermore, letro-
zole causes temporary accumulation of androgens in the
ovarian follicles by blocking the conversion of androgens
to estrogens. The accumulated androgens may increase
the sensitivity of the growing follicles to FSH by increas-
ing the expression of FSH receptors [21].
Because letrozole has short half life (average 45
hours), its effect decreases during late follicular phase
and therefore estradiol produced by growing follicles
increases. The elevated estradiol levels suppress the
release of FSH. The drop in FSH levels causes atresia of
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mono-ovulation in most cycles. On the other hand, clo-
miphene citrate induces prolonged estrogen receptors
depletion in the brain and therefore the increased estra-
diol produced by the growing follicles is not capable of
central suppression of FSH release. This maintains the
release of high levels of FSH throughout the follicular
phase and therefore induces development of multiple
follicles [22].
Although mono-ovulation is the main advantage of
induction of ovulation with letrozole in patients with
PCOS who are often hyperresponders and at high risk

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Figure 1 Flow diagram of the study.
Table 1 Patients characteristics
Extended letrozole group
(n = 107)
Clomiphene citrate group
(n = 107)
P value
Age (years) 26.68 ± 3.51 26.13 ± 3.22 0.233
Body mass index (Kg/m
2) 26.08 ± 3.55 25.24 ± 4.01 0.110
Duration of infertility(years) 3.69 ± 1.88 3.40 ± 1.62 0.229
Primary infertility 70/107(65.42%) 77/107(71.96%) 0.302
Secondary infertility 37/107(34.58%) 30/107(28.04%) 0.302
Day 2 FSH(IU/L) 5.71 ± 1.95 5.51 ± 1.85 0.451
Day 2 LH(IU/L) 4.94 ± 1.89 5.14 ± 1.94 0.443
Day 2 Estradiol(pg/ml) 53.21 ± 13.45 50.47 ± 12.08 0.119
Values are expressed as mean ± SD or n/n (%).
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unexplained infertility undergoing IUI [9]. Several stu-
dies revealed that the number of mature follicles is an
important predictor factor for the success of IUI cycle.
Sikander et al reported that the pregnancy rate per cycle
after IUI was 6.2%, 12.9% and 30% with one, two and
three mature follicles developed respectively [23].
The majority of studies comparing clomiphene citrate
with letrozole for superovulation in patients with unex-
plained infertility undergoing IUI revealed that although
letrozole induced fewer mature follicles compared with
clomiphene citrate the pregnancy rate was comparable
between both management options[9,12]. We think that
letrozole resulted in comparable pregnancy rate as clomi-
phene citrate, in spite of less number of mature oocytes
induced, because it has no adverse effect on endome-
trium. Boa et al found that the markers of endometrial
receptivity (HOXA10 and integrin alpha (v) beta (3)) in
rats were suppressed by clomiphene citrate and not
affected by letrozole [24]. Moreover, Cortinez reported
that letrozole administration in infertile ovulatory
women was associated with in-phase histological dating
of endometrium and normal pinopode expression [10].
I nt h ep r e s e n ts t u d y ,t h en u m b e ro fm a t u r eo o c y t e s
was similar between both groups and the pregnancy rate
per cycle and cumulative pregnancy rate were signifi-
cantly greater in the extended letrozole group (18.96%
Vs 11.43% and 37.73% Vs 22.86%, respectively).
There is only one study which reported the use of
extended letrozole regimen in induction of ovulation. In
that study, 218 patients with clomiphene citrate resistant
PCOS were randomized to receive letrozole 2.5 mg from
cycle day 1 to10 or letrozole 5 mg/day from cycle day 1 to
5. Extended letrozole regimen resulted in more mature
follicles and pregnancies than short letrozole regimen [17].
In natural cycles the rise of FSH levels during the
luteal-follicular transition phase stimulates the recruit-
ment and growth of a cohort of antral follicles. The
increase in the estradiol produced by the growing folli-
cles (mainly the dominant follicle) suppresses FSH levels
below the threshold required for the growth of all folli-
cles smaller than dominant follicle [25]. Meanwhile, the
dominant follicle continues to grow until the ovulatory
stage because it is more sensitive to FSH [26]. Badawy
et al suggested that the extended letrozole regimen can
maintain FSH levels above the threshold required for
the growth of follicles smaller than dominant follicle (i.
e. widen FSH window) and therefore induces multiple
ovulation [17].
The endometrial thickness was significantly greater in
the extended letrozole group. The results of our study
are in agree with the results of Metwally and Casper
and Sh Tehrani-Nejad et al [20,27]. On the other hand,
other studies revealed that the endometrial thickness
was comparable in patients treated with letrozole or clo-
miphene citrate [19,28]. In only one study, the endome-
trial thickness was significantly greater in the group of
patients treated with clomiphene citrate [29].
In patients with unexplained infertility undergoing IUI,
we think that the extended letrozole regimen is more
Table 2 Intrauterine insemination cycle characteristics
Extended letrozole group
(n = 106)
Clomiphene citrate group
(n = 105)
P value
No. of cycles completed 211 210
No. of follicles > 18 mm 2.24 ± 0.80 2.13 ± 0.76 0.154
Days of HCG administration 12.35 ± 1.05 12.50 ± 1.10 0.132
Endometrial thickness on HCG day (mm) 9.10 ± 1.84 8.18 ± 1.93 <0.001
Serum E2 on HCG day (pg/ml) 356 ± 151 822 ± 302 <0.001
Values are expressed as mean ± SD.
Table 3 Pregnancy outcomes
Extended letrozole group
(n = 106)
Clomiphene citrate group
(n = 105)
Odd ratio
(95% CI)
P value
No of completed cycles 211 210
Clinical pregnancy/cycle 40/211(18.96%) 24/210(11.43%) 1.81(1.05, 3.13) 0.031
Cumulative pregnancy rate 40/106(37.73%) 24/105(22.86%) 2.05(1.12, 3.73) 0.019
Ongoing pregnancy rate 35/106(33.02%) 20/105(19.05%) 2.09(1.11, 3.95) 0.02
Abortion rate 5/40(12.5%) 4/24(16.67%) 0.71(0.17, 2.97) 0.926
Multiple pregnancy rate 4/40(10%) 3/24(12.5%) 0.78(0.16, 3.82) 0.756
Ectopic pregnancy rate 0/40(0%) 0/24(0%) NA NA
OHSS 0/106 (0%) 0/105(0%) NA NA
Values are expressed as n/n (%).
CI = confidence interval, OHSS = ovarian hyperstimulation syndrome.
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because it induces multiple ovulation [17] and more
effective than clomiphene citrate because it has no
adverse effect on endometrium [20]. Several studies
revealed that the combination of exogenous gonadotro-
pins with letrozole increased the number of mature
oocytes and therefore improved the outcome of IUI
cycles in patients with unexplained infertility [6,12].
However, the addition of exogenous gonadotropins to
letrozole increases the cost of IUI cycle and is associated
with increased risk of higher order multiple pregnancy
and ovarian hyperstimulation syndrome. Our study
highlights the need for larger randomized controlled
trials to determine whether the extended letrozole regi-
men should be the treatment of choice for patients with
unexplained infertility undergoing IUI.
The results of the studies evaluating the safety of
letrozole are contradictory. In 2005, Bilijan et al com-
pared 150 babies born after letrozole therapy with
36000 babies born to low risk pregnant women.
Although the general incidence of anomalies was not
increased, the incidence of cardiac and bone anomalies
was higher in letrozole group [30]. Subsequent study
comparing 514 babies born after letrozole therapy with
36000 babies born after clomiphene citrate therapy
revealed that letrozole therapy was not associated with
increased risk of congenital anomalies [31]. In another
study, Forman et al. compared 112 babies born after
letrozole therapy with 271 babies born after clomiphene
citrate therapy and 94 newborns following spontaneous
pregnancy. The rate of malformations was 0%, 2.6%, and
3.2%, respectively [32].
In general, teratogenic agents must be present during
the period of embryogenesis (i.e. 18 to 54 day after ferti-
lization) to cause congenital anomalies, on the other
hand the exposure of embryo to teratogenic agents dur-
ing the preimplantation period (i.e. 8 to 10 days after
fertilization) does not cause congenital anomalies
[33,34]. Because letrozole is completely cleared in five
half lives after the last tablet is administered (i.e. about
ten days), Casper suggested that letrozole administration
in early follicular phase is not associated with any tera-
togenic effects because it is completely cleared before
implantation[35]. In the present study, letrozole was
stopped at least four days before IUI and therefore it
was completely cleared at least two days before
implantation.
Conclusion
The data presented in our study indicated that the
extended letrozole regimen had a superior efficacy as com-
pared with clomiphene citrate in patients of unexplained
infertility undergoing superovulation combined with IUI.
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